title: Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments.
abstract: Only few reports are available on the epitope specificity of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in multiple sclerosis (MS). In the present study we provide a precise characterization of the epitope specificity of serum antibodies directed against the extracellular domain of MOG, including IgG, IgM and IgA immunoglobulin isotypes in 28 relapsing remitting MS patients and report that linear epitopes amino-acid (aa) 37-48 and aa42-53 are immunodominant. Recently experienced relapses intensified the anti-MOG peptide antibody response. Immunomodulatory treatment with interferon-beta or glatiramer-acetate had no major impact on the anti-MOG peptide immunoreactivity after 1 year of therapy.
authors.affiliation: Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Khalil
authors.forename: Markus
authors.initials: M
authors.lastname: Reindl
authors.forename: Andreas
authors.initials: A
authors.lastname: Lutterotti
authors.forename: Bettina
authors.initials: B
authors.lastname: Kuenz
authors.forename: Rainer
authors.initials: R
authors.lastname: Ehling
authors.forename: Claudia
authors.initials: C
authors.lastname: Gneiss
authors.forename: Peter
authors.initials: P
authors.lastname: Lackner
authors.forename: Florian
authors.initials: F
authors.lastname: Deisenhammer
authors.forename: Thomas
authors.initials: T
authors.lastname: Berger
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D000906:Antibodies / Q000097:blood*; D000918:Antibody Specificity / Q000502:physiology*; D016022:Case-Control Studies; D000939:Epitopes / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000517:prevention & control / Q000628:therapy*; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D063308:Myelin-Oligodendrocyte Glycoprotein; D012372:ROC Curve; D055502:Secondary Prevention; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D000906:Antibodies; D000939:Epitopes; D007155:Immunologic Factors; C571326:MOG protein, human; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein